Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Down 9.3% in October

Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 19,900,000 shares, a decrease of 9.3% from the October 15th total of 21,940,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the short-interest ratio is presently 8.3 days.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD traded down $0.18 during mid-day trading on Tuesday, hitting $9.48. 1,336,624 shares of the stock were exchanged, compared to its average volume of 2,719,973. The company has a market cap of $2.83 billion, a P/E ratio of -27.91 and a beta of 0.68. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.57. The stock’s fifty day simple moving average is $10.96 and its two-hundred day simple moving average is $10.61.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $10,382,718.34. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 30,401 shares of company stock valued at $352,038 over the last quarter. Company insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP increased its position in Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after acquiring an additional 2,856,101 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Amicus Therapeutics by 20.1% during the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after buying an additional 2,307,385 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in Amicus Therapeutics by 583.4% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,176,600 shares of the biopharmaceutical company’s stock valued at $25,640,000 after buying an additional 1,858,100 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Amicus Therapeutics by 1,758.9% during the 2nd quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock worth $18,790,000 after buying an additional 1,792,277 shares during the last quarter. Finally, William Blair Investment Management LLC boosted its holdings in shares of Amicus Therapeutics by 12.8% during the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock worth $128,993,000 after acquiring an additional 1,477,084 shares during the period.

Analyst Upgrades and Downgrades

FOLD has been the subject of a number of research analyst reports. Bank of America lifted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Morgan Stanley lowered their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. Guggenheim increased their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald lifted their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.63.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.